Societal CDMO, Inc.
SCTL evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Lead Asset:
- verapamil sr (Approved)
What it means
What to watch
Prepared research question
What matters most for SCTL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
verapamil sr (Approved)
Next Catalyst
—
Tracking 1 pipeline candidate for Societal CDMO, Inc..
Run Societal CDMO, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Societal CDMO, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is Societal CDMO, Inc.'s lead drug candidate?
Societal CDMO, Inc.'s most advanced tracked candidate is verapamil sr (Approved) for Hypertension.
Who is the CEO of Societal CDMO, Inc.?
David Enloe, Jr. is the chief executive officer of Societal CDMO, Inc. (SCTL).
What therapeutic areas does Societal CDMO, Inc. focus on?
Societal CDMO, Inc. develops therapies across Neurology, Cardiovascular, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.